National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Lymphoma

Lymphoma is a cancer that begins in the immune cells of the lymphatic system and affects both adults and children. The lymphatic system is part of the body's immune system, which serves as the body's defense against infection.

Lymphoma occurs when an abnormal cell, usually a lymphocyte (a type of white blood cell) divides to make copies of itself. The abnormal cells do not die when they should, and the buildup of extra cells often forms a mass of tissue called a growth or tumor.

Lymphoma is separated into Hodgkin and non-Hodgkin lymphomas. Lymphomas are further divided into various subtypes based on biological features, ranging from indolent (slow-growing) to aggressive (fast-growing). Different lymphoma subtypes behave and respond differently to treatment.

More than 79,190* people in the United States will be newly diagnosed with lymphoma in 2012, with about 9,060* of them being diagnosed with Hodgkin lymphoma and about 70,130* with non-Hodgkin lymphoma.

Treatment options for lymphoma vary depending on the type of lymphoma, stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2012. Atlanta: American Cancer Society; 2012

Lymphoma Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with lymphoma. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Lymphoma
Phase III
Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
NCI-05-C-0252, NCT00118209

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
Phase II
A Multicenter, Open-label, Phase II, Safety and Efficacy Study of the Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory de novo Diffuse Large B-cell Lymphoma
NCI-11-C-0162, NCT01325701

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma
NCI-10-C-0052, NCT01092182

Principal Investigator:Referral Contact:
Kieron DunleavyPeggy Shovlin
301-435-1007301-594-6597
mshovlin@mail.nih.gov
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
NCI-10-C-0011, NCT01030900

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy
NCI-06-C-0051, NCT00267865

Principal Investigator:Referral Contact:
Robert YarchoanKaren Aleman
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
alemank@mail.nih.gov
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics
NCI-05-C-0170, NCT00114738

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
NCI-01-C-0030, NCT00006436

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin’s Lymphoma
NCI-93-C-0133 (Multi-center study), NCT00001337

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
Phase I/II
A Phase I/II Study of Tac-Expressing Malignancies (Other than ATL) with Yttrium-90 (90Y)-Radiolabeled Humanized Anti-Tac and Calcium-DTPA
NCI-97-C-0110, NCT00019305

Principal Investigator:Referral Contact:
Thomas WaldmannTat’Yana Worthy
301-496-6656301-496-0499
worthyt@mail.nih.gov
Phase I
Phase I Pilot Study of Topical Romidepsin in Patients With Stage IA, IB, or IIA Cutaneous T-Cell Non-Hodgkin’s Lymphoma
NCI-07-C-0133, NCT00477698

Principal Investigator:Referral Contact:
Heidi KongEffie Nomicos
301-402-7452301-402-6225 or
1-866-510-9104 (Toll Free)
enomicos@mail.nih.gov


  
Trial and Protocol Number
Hodgkin Lymphoma
Phase II
A Randomized Phase II Study Of Rituximab With ABVD Versus Standard ABVD for Subjects With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2)
NCI-10-C-0050, NCT00654732

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov
Phase I/II
Phase I/II Trial of Yttrium-90-labeled Daclizumab (anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin’s Lymphoma
NCI-12-C-0003, NCT01468311

Principal Investigator:Referral Contact:
Thomas WaldmannTat’Yana Worthy
301-496-6656301-496-0499
worthyt@mail.nih.gov


  
Trial and Protocol Number
Lymphomatoid Granulomatosis
Phase II
Treatment and Natural History Study of Lymphomatoid Granulomatosis
NCI-94-C-0074, NCT00018993

Principal Investigator:Referral Contact:
Wyndham H. WilsonPeggy Shovlin
301-435-2415301-594-6597
mshovlin@mail.nih.gov


  
Trial and Protocol Number
Graft-Versus-Host Disease
Phase II
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host Disease
NCI-12-C-0068, NCT01557517

Principal Investigator:Referral Contact:
Steven Z. PavleticKristen Cole
301-402-4899301-451-6569
colekr@mail.nih.gov


  
Trial and Protocol Number
Hematologic/Blood Cancers
Phase II
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
NCI-04-C-0055, NCT00074490

Principal Investigator:Referral Contact:
Daniel H. FowlerZetta Blacklock
301-435-8641301-594-2056
bblacklock@mail.nih.gov
Phase I/II
A Phase I/II Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
NCI-10-C-0067, NCT01086644

Principal Investigator:Referral Contact:
Robert J. KreitmanElizabeth Maestri
301-496-6947301-402-5633
maestrie@mail.nih.gov
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
NCI-09-C-0224, NCT00984165

Principal Investigator:Referral Contact:
Nancy M. HardyZetta Blacklock
301-451-1406301-594-2056
bblacklock@mail.nih.gov
Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia
NCI-09-C-0082, NCT00924326

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
NCI-08-C-0051, NCT00923910

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
NCI-07-C-0195, NCT00520130

Principal Investigator:Referral Contact:
Steven Z. PavleticZetta Blacklock
301-402-4899301-594-2056
bblacklock@mail.nih.gov
Phase I
Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History
NCI-11-C-0125, NCT01326728

Principal Investigator:Referral Contact:
Nancy M. HardyZetta Blacklock
301-451-1406301-594-2056
bblacklock@mail.nih.gov
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
NCI-10-C-0054, NCT01087294

Principal Investigator:Referral Contact:
James N. KochenderferZetta Blacklock
301-594-5340301-594-2056
bblacklock@mail.nih.gov
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
NCI-09-C-0210, NCT00973804

Principal Investigator:Referral Contact:
Steven Z. PavleticZetta Blacklock
301-402-4899301-594-2056
bblacklock@mail.nih.gov
A Phase I, Multi-Center, Dose Escalation Study of CAT-8015 in Pediatric Patients With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL)
NCI-08-C-0123, NCT00659425

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)

Multi-Institutional Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
NCI-06-C-0227, NCT00104923

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD)
NCI-04-C-0281, NCT00092235

Principal Investigator:Referral Contact:
Steven Z. PavleticZetta Blacklock
301-402-4899301-594-2056
bblacklock@mail.nih.gov
Hematologic Malignancy Biology Study
NCI-04-C-0102, NCT00923442

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)



  
Trial and Protocol Number
Pediatric Cancers
Phase I
A Phase I Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas
NCI-12-C-0091, NCT01568632

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms
NCI-11-C-0142, NCT01164163

Principal Investigator:Referral Contact:
Brigitte WidemannPediatric Oncology
301-496-7387301-496-4256
1-877-624-4878 (Toll free)

Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo® (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer
NCI-10-C-0220, NCT01222780

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)



  
Trial and Protocol Number
Solid Tumor
Phase II
Phase II Randomized Trial of the Combination of ABT-888 With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low Grade Non-Hodgkin’s Lymphoma
NCI-11-C-0080, NCT01306032

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
Phase I
A Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin’s Lymphoma
NCI-11-C-0150, NCT01581541

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
NCI-11-C-0060, NCT01273155

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
Pilot Study of Weekly EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
NCI-11-C-0042, NCT01251926

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors
NCI-11-C-0029, NCT01245218

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
NCI-11-C-0026, NCT01240577

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
NCI-10-C-0056, NCT01051635

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies
NCI-09-C-0111, NCT00923520

Principal Investigator:Referral Contact:
Susan BatesChristine Bryla
301-402-1357301-451-7868
brylacm@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov